Cannabis Bioscience Files 10-Q/A Amendment

Ticker: CBIH · Form: 10-Q/A · Filed: Oct 31, 2024 · CIK: 1411057

Sentiment: neutral

Topics: 10-Q/A, amendment, financials

TL;DR

CBIH filed an amended 10-Q for Aug 31, 2024. Check financials.

AI Summary

Cannabis Bioscience International Holdings, Inc. filed an amendment (No. 1) to its quarterly report on Form 10-Q/A for the period ended August 31, 2024. The filing, submitted on October 31, 2024, pertains to the company's operations and financial status during that quarter. The company, formerly known as CHINA INFRASTRUCTURE CONSTRUCTION Corp and FIDELITY AVIATION CORP, is incorporated in Colorado and headquartered in Houston, Texas.

Why It Matters

This filing provides updated information on the company's financial performance and operational status for the quarter ending August 31, 2024, which is crucial for investors to assess the company's current health.

Risk Assessment

Risk Level: medium — As a 10-Q/A filing, it indicates an amendment to a previous report, suggesting potential issues or corrections that require further investigation.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 10-Q/A filing?

This is Amendment No. 1 to the quarterly report on Form 10-Q for the period ended August 31, 2024, indicating updates or corrections to the original filing.

What is the reporting period for this filing?

The reporting period for this filing is the quarterly period ended August 31, 2024.

When was this amendment filed with the SEC?

This amendment was filed on October 31, 2024.

What were the previous names of Cannabis Bioscience International Holdings, Inc.?

The company was formerly known as CHINA INFRASTRUCTURE CONSTRUCTION Corp and FIDELITY AVIATION CORP.

Where is the principal executive office of the company located?

The principal executive office is located at 6201 Bonhomme Road, Suite 435N, Houston, TX 77036.

Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 15.6 · Accepted 2024-10-31 14:05:34

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 4

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 6. Exhibits 5

– FINANCIAL

PART I – FINANCIAL INFORMATION

Management’s

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Net Loss Net loss for the quarter ended August 31, 2024, was $76,305, compared with a net loss of $181,789 for the quarter ended August 31, 2023, for the reasons set forth above in relation to loss from operations ended August 31, 2024. If the Company had not incurred the non-cash expense of $100,000 described above, it would have recorded net income of $26,305 for the quarter ended August 31, 2024. Changes in Financial Condition and Results of Operations At August 31, 2024, the Company had a balance of $969 in cash and cash equivalents and accounts receivable of $17,176, negative working capital of $833,355 and no commitments for capital expenditures. At May 31, 2024, the Company had $755 in cash and cash equivalents and accounts receivable of $20,139, negative working capital of $860,416 and no commitments for capital expenditures. The Company had a negative balance of cash and cash equivalents of $579 on the date of this Report. 4

– OTHER INFORMATION

PART II – OTHER INFORMATION

Exhibits

Item 6. Exhibits. Exhibit Number Title 31 Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Accounting Officer 32 Section 1350 Certification of Principal Executive Officer and Principal Accounting Officer 5

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned thereunto duly authorized. CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. Date: October 31, 2024 By: /s/ Dante Picazo Dante Picazo Principal Executive Officer and Principal Accounting Officer 6

View Full Filing

View this 10-Q/A filing on SEC EDGAR

View on Read The Filing